SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocky9 who wrote (9667)8/31/2006 4:53:43 PM
From: Iamarangerboy  Read Replies (1) of 10280
 
thanks.... I have a hope that A-generic will have most of its impact on A, less impact on A-CR and perhaps much less impact on L itself. CLearly the pharmacies that perform routine generic substitutions will have an impact only A, whereas the "economic switching" by patients will impact all three, A A-CR and L.
anyone have word as to whether NBIX is proceeding with I, the two lower doses. I see that NBIX has had a small rally in the last couple of several days. SEPR is base building--- I hope.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News